Daiichi Sankyo today released its road map for the $3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some idea for drugmakers with products facing Ranbaxy generics of how quickly its revamp by Sun might put them in peril.
The FDA has been reviewing testosterone drugs since January of this year on concerns over their cardiovascular safety. Now, its across-the-pond counterpart is following suit, embarking on its own review following worrisome study data.
In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes from the second pharmacy benefits management report to be released in three days, this one from CVS Caremark following Express Scripts' missive on Tuesday.
Ever since Gilead's $1,000-per-day hepatitis C pill Sovaldi stormed the market late last year, the company has been under pressure from legislators, insurers, and patient advocacy groups to lower its price. Now, doctors are weighing in on the debate.
India may now be taking compulsory licensing one step further, with domestic Natco Pharma asking the country's patent office to deny Gilead Sciences protection on its brand-new hep C treatment in the first place.
A strong regulatory agency and the patient confidence it inspires are essential for both patients and the industry as a whole, Sanofi CEO Chris Viehbacher said Thursday. And while the FDA has made recent strides in restoring the patient trust the agency depends on, Commissioner Margaret Hamburg says it still has some work to do.
Its deal for Arab Pharmaceutical Product Company (Arabio) to manufacture Humira and other drugs in the kingdom is seen as a significant advance in the country's ability to manufacture biologics.
Hospira is one step closer to selling a Herceptin biosimilar in Britain. The U.S.-based drugmaker persuaded a U.K. court to overturn two Roche patents on the drug. And that means, as of now, Herceptin (trastuzumab) could be open to biosim competition when its main patent expires July 28.
With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.
Just weeks after Roche released data backing its claim that its hit drug Tamiflu saved lives during the H1N1 swine flu epidemic of 2009, a new study finds no evidence that the product stops the spread of the flu or reduces its complications.
The French Competition Authority has stepped up its probe of potential Lucentis price-fixing. As The Times of London reports, the antitrust regulators said they raided local offices of Roche and Novartis, looking for evidence of collusion.
Novartis, amid a company-wide strategic review, has said some of its underperforming units may be on the way out. But as it draws up its blueprints for the future, it's also working to bolster its star businesses, and Wednesday it announced some changes at the top of two of its key divisions.
Express Scripts released more stunning numbers on what could happen with spending on drugs to treat hepatitis C as it builds a case against the price Gilead Sciences has put on a drug that can cure the disease.
On Monday, Teva asked Supreme Court Chief Justice John Roberts to consider a plea to block generic competition to Copaxone until SCOTUS has weighed its appeal. And now, he wants to know what generics makers think about it.
Pharma spent even less on digital advertising last year than in 2012, and the online share of DTC was already small to begin with.
Mention Ranbaxy drugs to some wholesalers and U.S. doctors these days, and they will respond negatively. And so the Ranbaxy brand looks to be on its way out when Sun Pharmaceutical completes its $3.2 billion acquisition of Ranbaxy Laboratories later this year.
After Massachusetts Gov. Deval Patrick banned Zogenix's powerful new FDA-approved painkiller, Zohydro, the company filed a lawsuit arguing the ban was unconstitutional. On Tuesday, federal district court judge Rya Zobel said she was inclined to agree with Zogenix and was leaning towards granting a preliminary injunction that would allow Zohydro to be sold in Massachusetts.
A Johnson & Johnson number cruncher says nuggets of marketing gold are waiting to be found on its parenting site BabyCenter.
A Louisiana jury pummeled Takeda Pharmaceutical and Eli Lilly & Co. with $9 billion in punitive damages in a liability suit over their blockbuster diabetes drug Actos. It's one for the record books, an amount so far beyond normal that even the victorious lawyers discounted it.
Boehringer Ingelheim, determined not to let clot-fighter Pradaxa be outdone by Bayer and Johnson & Johnson's Xarelto, has added a couple of new uses to the drug's label, snagging the FDA's okay to treat deep vein thrombrosis (DVT) and pulmonary embolism (PE) in some patients. But it still has a long way to go--and some safety concerns to dispel--before it can retake the anticoagulant throne.